RESUMEN
Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are two severe autoimmune bullous diseases of the mucosae and/or skin associated with autoantibodies directed against desmoglein (Dsg) 3 and/or Dsg1. These two desmosomal cadherins, typifying stratified epithelia, are components of cell adhesion complexes called desmosomes and represent extra-desmosomal adhesion receptors. We herein review the advances in our understanding of the immune response underlying pemphigus, including human leucocyte antigen (HLA) class II-associated genetic susceptibility, characteristics of pathogenic anti-Dsg antibodies, antigenic mapping studies as well as findings about Dsg-specific B and T cells. The pathogenicity of anti-Dsg autoantibodies has been convincingly demonstrated. Disease activity and clinical phenotype correlate with anti-Dsg antibody titers and profile while passive transfer of anti-Dsg IgG from pemphigus patients' results in pemphigus-like lesions in neonatal and adult mice. Finally, adoptive transfer of splenocytes from Dsg3-knockout mice immunized with murine Dsg3 into immunodeficient mice phenotypically recapitulates PV. Although the exact pathogenic mechanisms leading to blister formation have not been fully elucidated, intracellular signaling following antibody binding has been found to be necessary for inducing cell-cell dissociation, at least for PV. These new insights not only highlight the key role of Dsgs in maintenance of tissue homeostasis but are expected to progressively change pemphigus management, paving the way for novel targeted immunologic and pharmacologic therapies.
Asunto(s)
Pénfigo/diagnóstico , Pénfigo/etiología , Animales , Anticuerpos Monoclonales/inmunología , Autoanticuerpos/genética , Autoanticuerpos/inmunología , Autoantígenos/inmunología , Desmogleínas/inmunología , Progresión de la Enfermedad , Epítopos/inmunología , Predisposición Genética a la Enfermedad , Humanos , Sueros Inmunes/inmunología , Idiotipos de Inmunoglobulinas/genética , Idiotipos de Inmunoglobulinas/inmunología , Mutación , Especificidad de Órganos/inmunología , Pénfigo/epidemiología , Pénfigo/terapia , Transducción de Señal , Subgrupos de Linfocitos T/inmunología , Subgrupos de Linfocitos T/metabolismo , Investigación Biomédica TraslacionalRESUMEN
We report on the safety and immunogenicity of idiotypic DNA vaccination in a phase I, non-randomised, open-label study in patients with multiple myeloma. The study used DNA fusion gene vaccines encoding patient-specific single chain variable fragment, or idiotype (Id), linked to fragment C (FrC) of tetanus toxin. Patients in complete or partial response following high-dose chemotherapy and autologous stem cell transplant were vaccinated intramuscularly with 1 mg DNA on six occasions, beginning at least 6 months post-transplant; follow-up was to week 52. Fourteen patients were enrolled on study and completed vaccinations. Idiotypic DNA vaccines were well tolerated with vaccine-related adverse events limited to low-grade constitutional symptoms. FrC- and Id-specific T-cell responses were detected by ex vivo ELISPOT in 9/14 and 3/14 patients, respectively. A boost of pre-existing anti-FrC antibody (Ab) was detected by ELISA in 8/14 patients, whilst anti-Id Ab was generated in 1/13 patients. Overall, four patients (29 %) made an immune response to FrC and Id, with six patients (43 %) responding to FrC alone. Over the 52-week study period, serum paraprotein was undetectable, decreased or remained stable for ten patients (71 %), whilst ongoing CR/PR was maintained for 11 patients (79 %). The median time to progression was 38.0 months for 13/14 patients. Overall survival was 64 % after a median follow-up of 85.6 months.
Asunto(s)
Vacunas contra el Cáncer/uso terapéutico , Mieloma Múltiple/terapia , Linfocitos T/inmunología , Vacunas de ADN/uso terapéutico , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Inmunidad Humoral , Idiotipos de Inmunoglobulinas/genética , Activación de Linfocitos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/inmunología , Mieloma Múltiple/mortalidad , Estadificación de Neoplasias , Fragmentos de Péptidos/genética , Proteínas Recombinantes de Fusión/genética , Análisis de Supervivencia , Toxina Tetánica/genéticaRESUMEN
Systemic lupus erythematosus (SLE) is marked by a Th cell-dependent B cell hyperresponsiveness, with frequent germinal center reactions and hypergammaglobulinemia. The specificity of Th cells in lupus remains unclear, but B cell Ids have been suggested. A hallmark is the presence of anti-dsDNA, mutated IgG autoantibodies with a preponderance of arginines in CDR3 of the Ig variable H chain (IgVH). B cells can present V region-derived Id peptides on their MHC class II molecules to Id-specific Th cells. We show that Id-specific Th cells support the proliferation of anti-dsDNA Id(+) B cells in mice suffering from systemic autoimmune disease with SLE-like features. Mice developed marked clonal expansions of B cells; half of the IgVH sequences were clonally related. Anti-dsDNA B cells made up 40% of B cells in end-stage disease. The B cells expressed mutated IgVH with multiple arginines in CDR3. Hence, Id-driven T cell-B cell collaboration supported the production of classical anti-dsDNA Abs, recapitulating the characteristics of such Abs in SLE. The results support the concept that Id-specific Th cells may trigger the development of SLE and suggest that manipulation of the Id-specific T cell repertoire could play a role in treatment.
Asunto(s)
Anticuerpos Antinucleares/inmunología , Selección Clonal Mediada por Antígenos/inmunología , ADN/inmunología , Lupus Eritematoso Sistémico/inmunología , Linfocitos T Colaboradores-Inductores/inmunología , Animales , Anticuerpos Antinucleares/biosíntesis , Arginina/química , Linfocitos B/inmunología , Secuencia de Bases , Hipergammaglobulinemia/inmunología , Inmunoglobulina G/inmunología , Cadenas Pesadas de Inmunoglobulina/genética , Cadenas Pesadas de Inmunoglobulina/inmunología , Idiotipos de Inmunoglobulinas/genética , Idiotipos de Inmunoglobulinas/inmunología , Región Variable de Inmunoglobulina/genética , Activación de Linfocitos/inmunología , Ratones , Ratones Endogámicos BALB C , Ratones Transgénicos , Análisis de Secuencia de ADNRESUMEN
Available therapies for lymphoplasmacytic lymphoma (LPL) provide no survival advantage if started before signs or symptoms of end-organ damage develop; hence, current recommendations are to follow a program of observation while patients are in the asymptomatic phase of disease. We hypothesize that using idiotypic determinants of a B-cell lymphoma's surface immunoglobulin as a tumor-specific marker, we can develop patient-specific chemokine-idiotype fusion DNA vaccines that induce an immune response against LPL. By activating the host immune system against the tumor antigen, we postulate that disease control of asymptomatic phase lymphoplasmacytic lymphoma can be maintained. These chemokine-idiotype fusion DNA vaccines provide protection in a lymphoma mouse model and have recently entered clinical trials. Herein, we describe procedures for the generation of therapeutic vaccines, particularly "second-generation" recombinant vaccines. Specifically, in the Methods section we describe how to identify lymphoma-associated immunoglobulin V (IgV) genes from patient biopsy and how to assemble these genes as single-chain variable gene fragment (scFv) in-frame with MIP-3α to generate novel DNA fusion vaccines.
Asunto(s)
Vacunas contra el Cáncer/genética , Idiotipos de Inmunoglobulinas/genética , Linfoma/inmunología , Linfoma/patología , Medicina de Precisión/métodos , Anticuerpos de Cadena Única/genética , Vacunas de ADN/genética , Vacunas de ADN/inmunología , Secuencia de Aminoácidos , Vacunas contra el Cáncer/inmunología , Células Clonales/metabolismo , Clonación Molecular , ADN Complementario/genética , Humanos , Idiotipos de Inmunoglobulinas/química , Idiotipos de Inmunoglobulinas/inmunología , Datos de Secuencia Molecular , Plásmidos/genética , Análisis de Secuencia de ADN , Anticuerpos de Cadena Única/química , Anticuerpos de Cadena Única/inmunologíaRESUMEN
Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy both in Europe and in the United States. Follicular lymphoma (FL), a tumor comprised of mature B cells, represents one fourth of all NHL and, despite good response rates to standard treatments, tends to frequently relapse to such an extent that it is still considered incurable. Among several alternative therapeutic options actively being pursued, immunotherapy by idiotypic vaccination is in the forefront of clinical experimental medicine. The idiotype vaccine consists of the tumor-specific immunoglobulin conjugated with keyhole limpet hemocyanin (KLH) and administered together with an adjuvant. Over the last 20 years, researchers have proven that this vaccine can induce specific immune responses. Too, those patients with such responses experience a disease-free survival longer than normally achievable, although these latter results require further confirmation in large clinical trials. Traditionally, idiotype vaccines have been produced through hybridoma technology. In this chapter this technology is described.
Asunto(s)
Vacunas contra el Cáncer/biosíntesis , Hibridomas/metabolismo , Idiotipos de Inmunoglobulinas/biosíntesis , Animales , Vacunas contra el Cáncer/genética , Vacunas contra el Cáncer/inmunología , Vacunas contra el Cáncer/metabolismo , Fusión Celular , Línea Celular , Línea Celular Tumoral , Supervivencia Celular , Criopreservación , Medios de Cultivo Condicionados , Electroforesis , Hemocianinas/metabolismo , Humanos , Hibridomas/citología , Idiotipos de Inmunoglobulinas/genética , Idiotipos de Inmunoglobulinas/inmunología , Idiotipos de Inmunoglobulinas/metabolismo , Ganglios Linfáticos/patología , Ratones , Análisis de SecuenciaRESUMEN
AIM: Idiotype, the unique part of immunoglobulin molecule expressed on the surface of B-cells, represents a specific antigen for vaccination against lymphoma. We have developed a rapid method for immunoglobulin variable fragments cloning, assembling and expression of recombinant idiotype protein in Escherichia coli. METHODS: PCR with specially designed panel of primers was used for direct amplification of variable regions of tumor immunoglobulin. Overlapping extension PCR, restriction and ligation was applied for assembling and cloning of vaccine construction. Idiotype protein was purified by metal-chelate chromatography. RESULTS: Methods of idiotype cloning from lymphoma cells and production of recombinant protein were developed and optimized. Several samples of idiotypic proteins originating from B-cell lines and lymphoma patients were produced. CONCLUSION: The proposed method of vaccine production is relatively cheap, not very laborious and requires as long as 6-7 week to perform. The expressed protein was soluble, did not accumulate in inclusion bodies and harvested at sufficient for vaccination quantity and concentration.
Asunto(s)
Anticuerpos Antineoplásicos/genética , Vacunas contra el Cáncer , Idiotipos de Inmunoglobulinas/genética , Linfoma de Células B/inmunología , Anticuerpos de Cadena Única/genética , Anticuerpos Antineoplásicos/inmunología , Linfocitos B/inmunología , Secuencia de Bases , Vacunas contra el Cáncer/genética , Vacunas contra el Cáncer/inmunología , Línea Celular Tumoral , Clonación Molecular , Escherichia coli/genética , Amplificación de Genes , Humanos , Inmunoglobulina G/genética , Inmunoglobulina G/inmunología , Idiotipos de Inmunoglobulinas/inmunología , Cadenas Ligeras de Inmunoglobulina/genética , Cadenas Ligeras de Inmunoglobulina/inmunología , Inmunoglobulina M/genética , Inmunoglobulina M/inmunología , Cadenas kappa de Inmunoglobulina/genética , Cadenas kappa de Inmunoglobulina/inmunología , Anticuerpos de Cadena Única/inmunologíaRESUMEN
A methodology based on the representation of each amino acid of a protein sequence by the electron-ion interaction potential and subsequent analysis by signal processing was used to determine the characteristic or common frequency (in Hz) that reflects the biological activity shared among phosphocholine (PC)-binding antibodies. The common frequency for the variable portion of the heavy chain (VH) of the PC-specific antibodies is found to be at f = 0.37 Hz. The VH sequences of the PC-binding antibodies exhibit three subsites for the PC moiety where hypervariable region 2 (CDR2) plays a role in the interaction with the phosphate group. Mutations in this VH region have an impact on the ability of mutant variants to bind PC and its carrier molecule, as well as on the characteristic frequency shift toward f = 0.12 Hz for mutants failing to bind both hapten and carrier. The VH sequence of mutants that retain the ability to bind PC still shows f = 0.37 Hz, suggesting that this frequency determines PC binding. However, this statement was not confirmed as mutation in another PC subsite impairs PC binding but retains both the phosphate-group recognition and the frequency at f = 0.37 Hz. Herein, this finding is discussed to promote the idea that the VH sequence of the PC-binding antibodies encodes the subsite for phosphate-group binding as a dominant functional activity and that only CDR2 of the T15-idiotype antibodies together with FR3 region form an autonomous self-association function represented by the T15VH50-73 peptide with f = 0.37±0.05 Hz. Thus, these data confirmed that T15VH50-73 peptide might be used in superantibody technology.
Asunto(s)
Anticuerpos/inmunología , Idiotipos de Inmunoglobulinas/química , Idiotipos de Inmunoglobulinas/inmunología , Región Variable de Inmunoglobulina/química , Región Variable de Inmunoglobulina/inmunología , Fosforilcolina/inmunología , Animales , Sitios de Unión/inmunología , Idiotipos de Inmunoglobulinas/genética , Región Variable de Inmunoglobulina/genética , RatonesRESUMEN
BACKGROUND: The mechanisms driving the development of immunoglobulin E (IgE) antibody repertoires are a matter of debate. Alternatives to the classical view on antibody development, involving somatic mutation and antigen-driven selection of high-affinity variants in germinal centers, have been proposed. METHODS: We have re-analyzed the pattern of mutations in previously isolated and characterized human clonally unrelated IgE-encoding transcripts using the validated focused binomial methodology to find evidence in such genes of antigen-specific selection. RESULTS: As expected there is a selection against replacement mutations in IgE framework regions. In contrast, in all examined cases but one (assessing IgE repertoires of parasite-infected individuals) there was no evidence in favor of either positive or negative selection in complementarity determining regions. Importantly, however, the validated method also failed to detect selection for replacement mutations in two, non-IgE, hypermutated antibody populations targeting tetanus toxoid and vaccinia virus, respectively. CONCLUSIONS: Current methodology is unable to define with certainty, using commonly assessed IgE repertoire sizes, whether antigen selection is or is not a major driving force in the establishment of human IgE. New approaches are needed to address this matter.
Asunto(s)
Inmunoglobulina E/genética , Inmunoglobulina E/inmunología , Mucosa Nasal/inmunología , Rinitis Alérgica Perenne/inmunología , Codón , Regiones Determinantes de Complementariedad/genética , Regiones Determinantes de Complementariedad/inmunología , Epítopos/genética , Epítopos/inmunología , Humanos , Cadenas Pesadas de Inmunoglobulina/genética , Cadenas Pesadas de Inmunoglobulina/inmunología , Idiotipos de Inmunoglobulinas/genética , Idiotipos de Inmunoglobulinas/inmunología , Leucocitos Mononucleares/inmunología , Modelos Estadísticos , Mutación , Rinitis Alérgica , Rinitis Alérgica Perenne/genéticaRESUMEN
Bipolar, amacrine, and retinal ganglion cells elaborate arbors and form synapses within the inner plexiform layer (IPL) of the vertebrate retina. Specific subsets of these neuronal types synapse in one or a few of the ≥10 sublaminae of the IPL. Four closely related Ig superfamily transmembrane adhesion molecules--Sidekick1 (Sdk1), Sdk2, Dscam, and DscamL--are expressed by non-overlapping subsets of chick retinal neurons and promote their lamina-specific arborization (Yamagata and Sanes, 2008). Here, we asked whether contactins (Cntns), six homologs of Sdks and Dscams, are expressed by and play roles in other subsets. In situ hybridization showed that cntn1-5 were differentially expressed by subsets of amacrine cells. Immunohistochemistry showed that each Cntn protein was concentrated in a subset of IPL sublaminae. To assess roles of Cntns in retinal development, we focused on Cntn2. Depletion of Cntn2 by RNA interference markedly reduced the ability of Cntn2-positive cells to restrict their arbors to appropriate sublaminae. Conversely, ectopic expression of cntn2 redirected neurites of transduced neurons to the Cntn2-positive sublaminae. Thus, both loss- and gain-of-function strategies implicate Cntn2 in lamina-specific neurite targeting. Studies in heterologous cells showed that Cntn2 mediates homophilic adhesion, but does not bind detectably to Sdks, Dscams, or other Cntns. Overexpression analysis showed that Cntns1 and 3 can also redirect neurites to appropriate sublaminae. We propose that Cntns, Sdks, and Dscams comprise an Ig superfamily code that uses homophilic interactions to promote lamina-specific targeting of retinal dendrites in IPL.
Asunto(s)
Contactina 2/fisiología , Regulación del Desarrollo de la Expresión Génica , Idiotipos de Inmunoglobulinas/genética , Retina/embriología , Retina/metabolismo , Animales , Membrana Basal/metabolismo , Pollos , Contactina 2/biosíntesis , Contactina 2/genética , Contactinas/biosíntesis , Contactinas/fisiología , Femenino , Células HEK293 , Humanos , Idiotipos de Inmunoglobulinas/biosíntesis , Células K562 , Ratones , Ratones Endogámicos BALB C , Ratones NoqueadosRESUMEN
Long-lived secreted autoantibody responses in systemic autoimmunity are generally regarded to be polyclonal and to express a diverse B-cell repertoire. Here, we have used a proteomic approach based on de novo sequencing to determine the clonality and V region structures of human autoantibodies directed against a prototypic systemic autoantigen, Ro52 (TRIM21). Remarkably, anti-Ro52 autoantibodies from patients with primary Sjögren's syndrome, systemic lupus erythematosus, systemic sclerosis or polymyositis were restricted to two IgG1 kappa clonotypes that migrated as a single species on isoelectric focusing; shared a common light chain paired with one of two closely-related heavy chains; and were public in unrelated patients. Targeted mass spectrometry using these uniquely mutated V region peptides as surrogates detected anti-Ro52 autoantibodies in human sera with high sensitivity and specificity compared with traditional ELISA. Mass spectrometry-based detection of specific autoantibody motifs provides a powerful new tool for analysis of humoral autoimmunity.
Asunto(s)
Autoanticuerpos/inmunología , Inmunoglobulina G/inmunología , Idiotipos de Inmunoglobulinas/inmunología , Cadenas kappa de Inmunoglobulina/inmunología , Proteoma/inmunología , Ribonucleoproteínas/inmunología , Síndrome de Sjögren/inmunología , Adulto , Anciano , Autoanticuerpos/sangre , Autoanticuerpos/genética , Autoinmunidad/genética , Estudios de Casos y Controles , Femenino , Expresión Génica/inmunología , Humanos , Inmunidad Humoral/genética , Inmunoglobulina G/sangre , Inmunoglobulina G/genética , Idiotipos de Inmunoglobulinas/sangre , Idiotipos de Inmunoglobulinas/genética , Cadenas kappa de Inmunoglobulina/sangre , Cadenas kappa de Inmunoglobulina/genética , Focalización Isoeléctrica , Masculino , Espectrometría de Masas , Persona de Mediana Edad , Péptidos/inmunología , Proteoma/genética , Ribonucleoproteínas/genética , Sensibilidad y Especificidad , Síndrome de Sjögren/sangre , Síndrome de Sjögren/diagnóstico , Síndrome de Sjögren/genéticaRESUMEN
The unique immunoglobulin idiotype expressed on the surface of B lymphoma cells can be used as an effective antigen in tumor-specific vaccines when fused to immunostimulatory proteins and cytokines. A DNA vaccine encoding for an idiotype antibody single chain Fv (scFv) fragment fused to the Tetanus Toxin Fragment C (TTFrC) has been shown to induce protective anti-tumor responses. Protein-based strategies may be more desirable since they provide greater control over dosage, duration of exposure, and in vivo distribution of the vaccine. However, production of fusion protein vaccines containing complex disulfide bonded idiotype antibodies and antibody-derived fragments is challenging. We use an Escherichia coli-based cell-free protein synthesis platform as well as high-level expression of E. coli inclusion bodies followed by refolding for the rapid generation of an antibody fragment - TTFrC fusion protein vaccine. Vaccine proteins produced using both methods were shown to elicit anti-tumor humoral responses as well as protect from tumor challenge in an established B cell lymphoma mouse model. The development of technologies for the rapid production of effective patient-specific tumor idiotype-based fusion protein vaccines provides opportunities for clinical application.
Asunto(s)
Vacunas contra el Cáncer/genética , Escherichia coli/genética , Idiotipos de Inmunoglobulinas/genética , Linfoma de Células B/prevención & control , Fragmentos de Péptidos/genética , Toxina Tetánica/genética , Vacunas de ADN/genética , Animales , Vacunas contra el Cáncer/inmunología , Vacunas contra el Cáncer/aislamiento & purificación , Vacunas contra el Cáncer/uso terapéutico , Femenino , Humanos , Inmunización , Idiotipos de Inmunoglobulinas/inmunología , Idiotipos de Inmunoglobulinas/aislamiento & purificación , Idiotipos de Inmunoglobulinas/uso terapéutico , Linfoma de Células B/inmunología , Ratones , Fragmentos de Péptidos/inmunología , Fragmentos de Péptidos/aislamiento & purificación , Fragmentos de Péptidos/uso terapéutico , Pliegue de Proteína , Toxina Tetánica/inmunología , Toxina Tetánica/aislamiento & purificación , Toxina Tetánica/uso terapéutico , Vacunas de ADN/inmunología , Vacunas de ADN/aislamiento & purificación , Vacunas de ADN/uso terapéuticoRESUMEN
Active immunization with the idiotype of follicular lymphoma induces tumor-specific immunity. T cells induced in vivo by idiotype vaccination recognize human leukocyte antigen (HLA)--restricted hypervariable but not conserved idiotype peptides. We hypothesized that idiotype-directed T-cell immunity occurs naturally and performed a reverse immunology analysis of idiotype HLA binding in 39 follicular lymphoma patients. For every idiotype, the sum of HLA-A or -B binding scores of the 20 highest-scoring peptides was calculated for all 39 HLA types through the BIMAS algorithm. The idiotype sum score of every patient's lymphoma was compared on the respective patient's HLA type to the mean of the sum scores of the remaining 38 idiotypes. Autologous idiotypes had lower immunogenicity than allogeneic idiotypes. Differential immunogenicity resided predominantly in all 3 complementarity-determining regions rather than in framework peptides. Idiotype immunogenicity was not changed by somatic hypermutation. These findings indicate T cell-mediated immunosurveillance of follicular lymphoma directed specifically against individual idiotype epitopes.
Asunto(s)
Antígenos HLA/inmunología , Idiotipos de Inmunoglobulinas/inmunología , Linfoma Folicular/inmunología , Linfocitos T/inmunología , Adulto , Anciano , Algoritmos , Alelos , Epítopos de Linfocito T/genética , Epítopos de Linfocito T/inmunología , Epítopos de Linfocito T/metabolismo , Femenino , Antígenos HLA/genética , Antígenos HLA/metabolismo , Antígenos HLA-A/genética , Antígenos HLA-A/inmunología , Antígenos HLA-A/metabolismo , Antígenos HLA-B/genética , Antígenos HLA-B/inmunología , Antígenos HLA-B/metabolismo , Humanos , Idiotipos de Inmunoglobulinas/genética , Idiotipos de Inmunoglobulinas/metabolismo , Linfoma Folicular/genética , Linfoma Folicular/metabolismo , Masculino , Persona de Mediana Edad , Monitorización Inmunológica/estadística & datos numéricos , Unión Proteica , Linfocitos T/citología , Linfocitos T/metabolismoRESUMEN
BACKGROUND: Animal and clinical studies with plant-produced single-chain variable fragment lymphoma vaccines have demonstrated specific immunogenicity and safety. However, the expression levels of such fragments were highly variable and required complex engineering of the linkers. Moreover, the downstream processing could not be built around standard methods like protein A affinity capture. DESIGN: We report a novel vaccine manufacturing process, magnifection, devoid of the above-mentioned shortcomings and allowing consistent and efficient expression in plants of whole immunoglobulins (Igs). RESULTS: Full idiotype (Id)-containing IgG molecules of 20 lymphoma patients and 2 mouse lymphoma models were expressed at levels between 0.5 and 4.8 g/kg of leaf biomass. Protein A affinity capture purification yielded antigens of pharmaceutical purity. Several patient Igs produced in plants showed specific cross-reactivity with sera derived from the same patients immunized with hybridoma-produced Id vaccine. Mice vaccinated with plant- or hybridoma-produced Igs showed comparable protection levels in tumor challenge studies. CONCLUSIONS: This manufacturing process is reliable and robust, the manufacturing time from biopsy to vaccine is <12 weeks and the expression and purification of antigens require only 2 weeks. The process is also broadly applicable for manufacturing monoclonal antibodies in plants, providing 50- to 1000-fold higher yields than alternative plant expression methods.
Asunto(s)
Vacunas contra el Cáncer/biosíntesis , Idiotipos de Inmunoglobulinas/metabolismo , Linfoma no Hodgkin/inmunología , Linfoma no Hodgkin/terapia , Planticuerpos/metabolismo , Agrobacterium tumefaciens/genética , Agrobacterium tumefaciens/inmunología , Agrobacterium tumefaciens/metabolismo , Animales , Vacunas contra el Cáncer/genética , Vacunas contra el Cáncer/inmunología , Vacunas contra el Cáncer/aislamiento & purificación , Clonación Molecular , Eficiencia , Regulación de la Expresión Génica de las Plantas , Humanos , Idiotipos de Inmunoglobulinas/genética , Idiotipos de Inmunoglobulinas/inmunología , Individualidad , Ratones , Ratones Endogámicos C3H , Planticuerpos/genética , Planticuerpos/aislamiento & purificación , Plantas Modificadas Genéticamente/genética , Plantas Modificadas Genéticamente/inmunología , Plantas Modificadas Genéticamente/metabolismo , Factores de Tiempo , Vacunas Sintéticas/biosíntesis , Vacunas Sintéticas/genética , Vacunas Sintéticas/inmunología , Vacunas Sintéticas/aislamiento & purificaciónRESUMEN
We evaluated the efficacy and safety of patient-specific immunotherapy with mitumprotimut-T idiotype keyhole limpet hemocyanin and granulocyte-monocyte colony-stimulating factor (GM-CSF) following rituximab in patients with follicular B-cell lymphoma. Patients with previously untreated or relapsed/refractory CD20+ follicular lymphoma received 4 weekly infusions of rituximab and those with a complete response (CR), partial response (PR), or stable disease received mitumprotimut-T and GM-CSF injections subcutaneously. Courses were given monthly for 6 doses, every 2 months for 6 doses, and then every 3 months until disease progression. Computed tomography scans were obtained every 3 to 6 months and reviewed centrally. The primary endpoint was event-free survival (EFS). Among 103 patients treated with rituximab, 92 (54 relapsed/refractory and 38 previously untreated) received mitumprotimut-T/GM-CSF; median age was 53 years, 91% had stage III to IV disease, and 59% had failed earlier therapy. The premitumprotimut-T objective response rate was 47% (2 CRs, 41 PRs). During the mitumprotimut-T treatment phase, 16 patients converted to CR resulting in an overall objective response rate of 60% (18 CRs, 37 PRs). Median EFS was 15.2, 20.8, and 13.5 months for all, treatment-naive, and relapsed/refractory disease patients, respectively. Anti-Id cellular immune responses were detected in 13 of 18 (72%) patients and humoral immune responses in 17 of 83 (20%) patients. Adverse events were usually mild-to-moderate. The most common adverse event was injection site reactions. Mitumprotimut-T/GM-CSF-induced anti-Id cellular immune responses in most patients. The occurrence of late CRs and favorable EFS suggested a clinical benefit of active immunotherapy and led to a placebo-controlled phase 3 trial.
Asunto(s)
Factor Estimulante de Colonias de Granulocitos y Macrófagos/administración & dosificación , Inmunoterapia , Linfoma de Células B/terapia , Linfoma Folicular/terapia , Proteínas Recombinantes de Fusión/administración & dosificación , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Antiidiotipos/sangre , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales de Origen Murino , Antígenos CD20/biosíntesis , Antígenos CD20/inmunología , Antígenos de Neoplasias/inmunología , Supervivencia sin Enfermedad , Femenino , Hemocianinas/genética , Hemocianinas/inmunología , Hemocianinas/metabolismo , Humanos , Inmunidad Humoral/efectos de los fármacos , Idiotipos de Inmunoglobulinas/genética , Idiotipos de Inmunoglobulinas/inmunología , Idiotipos de Inmunoglobulinas/metabolismo , Inyecciones Subcutáneas , Linfoma de Células B/inmunología , Linfoma de Células B/patología , Linfoma de Células B/fisiopatología , Linfoma Folicular/inmunología , Linfoma Folicular/patología , Linfoma Folicular/fisiopatología , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Proteínas Recombinantes , RituximabRESUMEN
Rapidly induced, specific Ab generated in extrafollicular foci are important components of early immune protection to influenza virus. The signal(s) that prompt B cells to participate in extrafollicular rather than germinal center responses are incompletely understood. To study the regulation of early B-cell differentiation events following influenza infection, we exploited earlier findings of a strong contribution of C12 idiotype-expressing B cells to the primary HA-specific response against influenza A/PR/8/34. Using an idiotype-specific mAb to C12 and labeled HA, in conjunction with multicolor flow cytometry, we followed the fate of C12Id-expressing influenza HA-specific B cells in WT BALB/c mice, requiring neither genetic manipulation nor adoptive cell transfer. Our studies demonstrate that HA-specific C12Id(+) B cells are phenotypically indistinguishable from follicular B cells. While they induced both extrafollicular and germinal center responses, extrafollicular responses were strongly predominant. Provision of increased HA-specific T-cell help increased the magnitude of the extrafollicular response, but did not shift the C12Id(+) response toward germinal center formation. Collectively the data are consistent with the hypothesis that B-cell fate determination following activation is a stochastic process in which infection-induced innate signals might drive the preferential expansion of the early extrafollicular response.
Asunto(s)
Anticuerpos Antivirales/inmunología , Linfocitos B/inmunología , Virus de la Influenza A/inmunología , Infecciones por Orthomyxoviridae/inmunología , Animales , Anticuerpos Monoclonales/genética , Anticuerpos Monoclonales/inmunología , Anticuerpos Antivirales/genética , Linfocitos B/metabolismo , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD4-Positivos/metabolismo , Ensayo de Inmunoadsorción Enzimática , Femenino , Citometría de Flujo , Centro Germinal/inmunología , Centro Germinal/metabolismo , Glicoproteínas Hemaglutininas del Virus de la Influenza/inmunología , Idiotipos de Inmunoglobulinas/genética , Idiotipos de Inmunoglobulinas/inmunología , Isotipos de Inmunoglobulinas/genética , Isotipos de Inmunoglobulinas/inmunología , Ganglios Linfáticos/inmunología , Ganglios Linfáticos/metabolismo , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Infecciones por Orthomyxoviridae/virologíaRESUMEN
Therapeutic vaccines have been developed to induce immune responses capable of eradicating lymphoma and myeloma tumors. Most of these vaccines target the immunoglobulin idiotype (Id) as a tumor-specific antigen. Phase I/II clinical trials of Id vaccination in lymphoma demonstrated that some lymphoma patients could mount immune responses that were correlated with a favorable clinical outcome. These encouraging results initiated phase III trials of Id vaccination in lymphoma, the results of which have been recently released. Disappointingly, only one of three phase III studies achieved the primary end point of progression-free survival. Detailed analysis of these results is awaited to help identify factors that determine clinical efficacy of Id vaccination as reflected in the three trials. Unlike lymphoma, studies of Id vaccination in multiple myeloma have yielded far less evidence of clinical benefit. Although Id vaccines induce immune responses in myeloma patients, their efficacy is insufficient to provide a clear clinical benefit. Strategies to improve lymphoma and myeloma vaccines are currently tested with an emphasis on optimization of antigen delivery and presentation and modulation of the immune system toward enhancement of T-cell function. Despite many hurdles yet to overcome, it is hoped that newly developed strategies that augment both immune and clinical responses will allow effective vaccination resulting in tumor eradication.
Asunto(s)
Vacunas contra el Cáncer/inmunología , Vacunas contra el Cáncer/uso terapéutico , Idiotipos de Inmunoglobulinas/inmunología , Linfoma de Células B/inmunología , Linfoma de Células B/terapia , Mieloma Múltiple/inmunología , Mieloma Múltiple/terapia , Animales , Ensayos Clínicos como Asunto , Humanos , Idiotipos de Inmunoglobulinas/genética , Linfoma de Células B/diagnóstico , Linfoma de Células B/genética , Mieloma Múltiple/diagnóstico , Mieloma Múltiple/genética , Resultado del TratamientoRESUMEN
Antibody fragments (scFvs) fused to luciferase reporter proteins have been used as highly sensitive optical imaging probes. Gaussia princeps luciferase (GLuc) is an attractive choice for a reporter protein because it is small and bright and does not require ATP to stimulate bioluminescence-producing reactions. Both GLuc and scFv proteins contain multiple disulfide bonds, and consequently the production of active and properly folded GLuc-scFv fusions is challenging. We therefore produced both proteins individually in active form, followed by covalent coupling to produce the intended conjugate. We used an Escherichia coli-based cell-free protein synthesis (CFPS) platform to produce GLuc and scFv proteins containing non-natural amino acids (nnAAs) for subsequent conjugation by azide-alkyne click chemistry. GLuc mutants with exposed alkyne reactive groups were produced by global replacement of methionine residues in CFPS. Antibody fragment scFvs contained a single exposed azide group using a scheme for site-specific incorporation of tyrosine analogs. Incorporation of tyrosine analogs at specific sites in proteins was performed using an engineered orthogonal tRNA-tRNA synthetase pair from an archaebacterium. The unique azide and alkyne side chains in GLuc and the antibody fragment scFv facilitated conjugation by click chemistry. GLuc-scFv conjugates were shown to differentiate between cells expressing a surface target of the scFv and cells that did not carry this marker.
Asunto(s)
Anticuerpos Antineoplásicos/biosíntesis , Copépodos/enzimología , Región Variable de Inmunoglobulina/biosíntesis , Luciferasas/biosíntesis , Linfoma de Células B/diagnóstico , Ingeniería de Proteínas , Secuencia de Aminoácidos , Animales , Anticuerpos Antineoplásicos/genética , Anticuerpos Antineoplásicos/inmunología , Escherichia coli/genética , Escherichia coli/metabolismo , Humanos , Idiotipos de Inmunoglobulinas/biosíntesis , Idiotipos de Inmunoglobulinas/genética , Idiotipos de Inmunoglobulinas/inmunología , Región Variable de Inmunoglobulina/genética , Región Variable de Inmunoglobulina/inmunología , Luciferasas/genética , Luciferasas/inmunología , Ratones , Datos de Secuencia Molecular , Biosíntesis de Proteínas , Proteínas Recombinantes de Fusión/biosíntesis , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/inmunologíaRESUMEN
Autoimmune type-II cryoglobulinemia (II-MC) is sustained by hepatitis C virus (HCV) infection and B-cell (oligo)clones. This is the reason why the disease may be considered an "indolent B-cell lymphoma (NHL)." B clones show a restricted use of immunoglobulin variable genes (BCR), in particular in the use of the variable kappa (VK)3-20/15 light chain, and show a homology between their BCR functional regions and those of autoimmune rheumatoid factors. We underlined the BCR unique repertoire with frequent rheumatoid factor activity also observed in other autoimmune disorders associated with NHL. The immunoglobulin idiotype is a clonal B-cell marker and an ideal target for immunotherapy. Five monoclonal antibodies were produced in our laboratory toward the VK3-20 of a subject with HCV infection and a II-MC-associated NHL. Epitope determination was performed using the epitope excision approach. Monoclonal antibody reactivity was tested in vitro in ELISA, Western blot, and cytofluorimetry. Data confirmed that a panel of antibodies, reactive against shared idiotypes, can be produced from patients with HCV-associated B-cell lymphoproliferative diseases, thus obviating the need to produce an anti-idiotype antibody for each patient.
Asunto(s)
Crioglobulinemia/inmunología , Idiotipos de Inmunoglobulinas/inmunología , Linfoma de Células B/inmunología , Animales , Anticuerpos Monoclonales/genética , Anticuerpos Monoclonales/inmunología , Linfocitos B/inmunología , Linfocitos B/patología , Linfocitos B/virología , Proliferación Celular , Ensayo de Inmunoadsorción Enzimática , Epítopos/genética , Epítopos/inmunología , Citometría de Flujo , Hepacivirus/inmunología , Hepatitis C/inmunología , Hepatitis C/virología , Humanos , Inmunización , Immunoblotting , Fragmentos de Inmunoglobulinas/genética , Idiotipos de Inmunoglobulinas/genética , Región Variable de Inmunoglobulina/genética , Cadenas kappa de Inmunoglobulina/genética , Ratones , Ratones Endogámicos BALB CRESUMEN
Antibodies against different chronic viruses, including hepatitis C virus (HCV), express a public cross-reactive idiotype (Id) designated as 1F7. The prominence of this Id may reflect selective engagement of B1 B cells by chronic pathogens. We investigated this by comparing 1F7 Id expression on CD5(+) and CD5(-) B cells, total IgG, total IgM and anti-HCV core antibodies in different HCV exposure settings. By flow cytometry, we observed a selective increase in 1F7 Id(+)CD5(+) B cells in chronic HCV infection. 1F7 Id levels in different immunoglobulin compartments were measured by enzyme-linked immunosorbent assay. 1F7 Id expression was prominent in anti-HCV core antibodies of approximately 90% of 141 HCV-exposed individuals tested. In the Canadian and Armenian study groups, participants who spontaneously cleared HCV infection had lower median 1F7 Id levels on total plasma IgG and anti-HCV core antibodies. Armenian spontaneous clearers, who were younger and more recently infected than their Canadian counterparts, also had had lower median 1F7 Id levels on total plasma IgM. Engagement by HCV of B-cell receptors within, or overlapping with the CD5(+) B1 B-cell repertoire is reflected in the production of 1F7 Id(+) anti-HCV antibodies and expansion of 1F7 Id(+)CD5(+) B cells. Higher 1F7 Id expression levels are associated with chronic infection.
Asunto(s)
Linfocitos B/metabolismo , Hepacivirus/inmunología , Anticuerpos contra la Hepatitis C/metabolismo , Hepatitis C Crónica/inmunología , Idiotipos de Inmunoglobulinas/metabolismo , Adulto , Armenia , Linfocitos B/inmunología , Linfocitos B/patología , Antígenos CD5/biosíntesis , Canadá , Separación Celular , Reacciones Cruzadas , Femenino , Citometría de Flujo , Hepacivirus/patogenicidad , Anticuerpos contra la Hepatitis C/genética , Anticuerpos contra la Hepatitis C/inmunología , Antígenos de la Hepatitis C/inmunología , Hepatitis C Crónica/sangre , Hepatitis C Crónica/patología , Hepatitis C Crónica/fisiopatología , Humanos , Inmunoglobulina G/sangre , Idiotipos de Inmunoglobulinas/genética , Idiotipos de Inmunoglobulinas/inmunología , Inmunoglobulina M/sangre , Masculino , Persona de Mediana Edad , Proteínas del Núcleo Viral/inmunologíaRESUMEN
The purpose of this study was to construct expression vectors of idiotype (Id) SmIg in patients with B-chronic lymphocytic leukemia and to express them in E.coli to obtain recombinant Id, and to investigate the effect of the protein on the proliferation and secretion of IL-2 and IFN-gamma of stimulated peripheral blood mononuclear cells (PBMC) in vitro. Light chain gene and Fd fragment of heavy chain gene were inserted into fd-tet-DOG2 vector to construct fd-tet-DOG2-Fab. Fab gene was further cloned into expression vector pHEN2 to construct the soluble expression vector pHEN2-Fab. After induction by IPTG, Fab protein was purified by Ni-NTA-chromatography. MTT was used to determine the effects of purified protein on the proliferation of stimulated PBMC in vitro and the concentrations of IL-2 and IFN-gamma in the culture supernatants were detected by ELISA. The results showed that recombinant pHEN2-Fab expression vector was constructed successfully. Fab protein was expressed in positive clone after induced by IPTG and two specific bands at 24-25 kD position were observed by SDS-PAGE electrophoresis. Proliferation of PBMC could be induced by purified Fab and the concentrations of IL-2 and IFN-gamma in culture supernatants were increased significantly after induction. It was suggested that the expression vector of SmIg Fab fragment was constructed successfully, and expressed and secreted from E. coli. The Fab protein could induce proliferation of PBMC and promote secretion of IL-2 and IFN-gamma.